HC Wainwright & Co. Maintains Buy on Orchestra BioMed Hldgs, Raises Price Target to $12
HC Wainwright & Co. analyst Yi Chen maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and raises the price target from $10 to $12.
Last updated: 2026-11-19 11:13:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Orchestra BioMed Holdings, Inc. (OBIO) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $7.68, with a market capitalization of $548.57M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.46 to $7.83. This page covers its latest market performance, valuation, price trends and company information.
$548.57M | |
$7.63 | |
$7.68 | |
$7.63 | |
$7.46 | |
94.00 | |
415.10K | |
-- | |
$7.83 | |
$3.46 | |
-- | |
2026-09-30 |
Orchestra BioMed Holdings, Inc. (OBIO) is trading at $7.68 in pre-market trading as of 2026-11-19 10:10:00, up 2.88% ($0.21) from the previous close of $7.46
Pre-market trading shows how investors are pricing OBIO before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Orchestra BioMed Holdings, Inc. (OBIO) moved from $5.73 to $7.68, representing a gain of 33.94% ($1.94).
The stock traded between $5.69 and $7.83 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 807.05 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 96.6%
OBIO is currently trading at $7.68, placing it 96.6% of the way from its 52-week low of $3.46 to its 52-week high of $7.83. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 86 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Orchestra BioMed Holdings, Inc. and OBIO stock.
HC Wainwright & Co. analyst Yi Chen maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and raises the price target from $10 to $12.
BTIG analyst Marie Thibault maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and raises the price target from $10 to $12.
Eligible investors can buy real shares of Orchestra BioMed Holdings, Inc. (OBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to OBIO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between OBIO shares and USD.
OBIO Shares to USD
1.00 OBIO shares = 7.675 USD
Calculations are estimates based on the latest available price and are for reference only.